Navigation Links
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Date:11/5/2012

PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients.  SAR236553/REGN727 is an investigational subcutaneously administered, fully-human antibody that is being evaluated for its impact on lowering low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The ODYSSEY OUTCOMES trial will enroll approximately 18,000 patients, who recently suffered an acute coronary syndrome (ACS), from 49 countries across six continents.  With the start of this study, eleven trials are now recruiting in the global SAR236553/REGN727 Phase 3 program.

"Despite widespread use of statin therapy, many patients at risk do not reach recommended targets for LDL.  Even among those who do reach targets, further LDL lowering may further reduce the risks of coronary heart disease (CHD) death, myocardial infarction (MI) and stroke," said Ph. Gabriel Steg M.D., Professor of Cardiology at the Hopital Bichat-Claude Bernard in Paris, France, and co-Chair of the ODYSSEY OUTCOMES Steering Committee.  "The ODYSSEY cardiovascular (CV) outcomes trial will test the efficacy and safety of SAR236553/REGN727 added to maximal doses of statins in reducing cardiovascular morbidity and mortality in patients with recent ACS, a population at high risk of CV events despite best contemporary therapy."

ODYSSEY OUTCOMES is a double-blind, randomized, placebo-controlled, multi-national study.  The primary objective of the study is to evaluate the effect of SAR236553/REGN727 on the incidence of cardiovascular events in patien
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Regeneron Announces June 2012 Investor Conference Presentations
8. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
9. Regeneron Announces September 2012 Investor Conference Presentations
10. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
11. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... announced that Mr. Ofir Paz, InspireMD,s co-founder and chief ... will participate in the Benchmark Company, LLC One-on-One Investor ... Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference ...
... Axcan Intermediate Holdings Inc. announces that it ... the recently completed combination of two specialty pharma companies ... also has a new corporate logo and website (please ... "Our new name, Aptalis, is intended to capture the ...
Cached Medicine Technology:InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 2The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 3
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:11/22/2014)... 22, 2014 The topic of B&D ... block retaining walls. The article states that, “While they give ... necessary steps that go into creating this powerful look.” , ... retaining wall is choosing which kind of block matches your ... B&D Rockeries says, “The two main options are concrete and ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... WEDNESDAY, Aug. 25 (HealthDay News) -- Even prior to ... in four American parents with health insurance reported that their ... medical care their children needed. Parents of kids with ... to say their insurance coverage did not meet their needs, ...
... and promise of using thermal ablation to target and ... of Vascular and Interventional Radiology ,s August supplement, "Thermal ... Goals and Future Technology." "The Journal ... on the development of multiple medical techniques and devices ...
... 11 states will receive more than $6 million in ... on substance abuse and associated problems among U.S. military ... Drug Abuse (NIDA), part of the National Institutes of ... to award grants that will examine substance abuse related ...
... treat metastatic melanoma tumors with a specific genetic signature was successful ... clinical trial. Results of the trial of PLX4032, an inhibitor ... half of all melanomas, appear in the August 26 New ... and is one of the top causes of cancer death in ...
... 25 Vitamin D may be an effective therapy to ... can cause severe complications for patients with cystic fibrosis and ... UPMC, the University of Pittsburgh School of Medicine and Louisiana ... by Jay Kolls, M.D., Ph.D., a lung disease researcher at ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
Cached Medicine News:Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 2Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 3Health News:Vitamin D may treat and prevent allergic reaction to mold in cystic fibrosis patients 2Health News:Study Links Gene to Serious Eye Disease 2
Inquire...
Inquire...
One Piece: Premier Pouches - Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Inquire...
Medicine Products: